When treating rectal cancer with neoadjuvant chemoRT, is it appropriate to employ IMRT planning, rather than 3D conformal, for all cases, or should IMRT be reserved for special circumstances?
Answer from: Radiation Oncologist at Academic Institution
Special circumstances.
When considering the use of IMRT for any disease site, one should always have evidence to support it over 3D CRT or at least a good rationale if there is a gap in the evidence.
For rectal cancer, there is not much evidence that IMRT reduces acute GI toxicity. The RTOG 0247 w...
Sign in or Register to read more